E-Newsletter - September 2022
Ongoing Alliance Trials


FOUR ONGOING ALLIANCE TRIALS ENROLLING PARTICIPANTS NOW

Alliance A032002 (Platinum Ineligible/Refractory Metastatic Urothelial Cancer)

Himanshu Nagar, MD, of Weill Cornell Medicine, leads Alliance A032002 (Phase II randomized trial of atezolizumab versus atezolizumab and radiation therapy for platinum ineligible/refractory metastatic urothelial cancer (ART)). This phase II trial compares the effect of adding radiation therapy to an immunotherapy drug called atezolizumab vs. atezolizumab alone in treating patients with urothelial cancer that has spread to other places in the body (metastatic). The addition of radiation to immunotherapy may shrink the cancer, but it could also cause side effects. Immunotherapy with monoclonal antibodies such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Stereotactic body radiation therapy (SBRT) is a type of radiation therapy that uses high energy x-rays to kill tumor cells and shrink tumors. This method uses special equipment to position a patient and precisely deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and may cause less damage to normal tissue than conventional radiation therapy. The combination of atezolizumab and radiation therapy may be more efficient in killing tumor cells. The trial opened on December 1, 2021. Learn more: https://bit.ly/Alliance-A032002 | Alliance Member Site

Alliance A051902 (Peripheral T-cell Lymphomas)

Neha Mehta-Shah, MD, of Washington University School of Medicine, leads Alliance A051902 (A randomized phase II study of CHO(E)P vs. oral azacitidine-CHO(E)P vs. duvelisib-CHO(E)P in previously untreated CD30 negative peripheral T-cell lymphomas). This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as CC-486, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help find out if this approach is better or worse than the usual approach for treating peripheral T-cell lymphoma. The trial opened on July 30, 2021. Learn more: https://bit.ly/Alliance-A051902 | Alliance Member Site

Alliance A081801 (ACCIO/Resected Non-small Cell Lung Cancer)

Jacob M. Sands, MD, of the Dana-Farber Cancer Institute, leads Alliance A080801 (Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST chemo-IO ). This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB IIIA or IIIB non-small cell lung cancer. The trial opened on June 3, 2020. Learn more: http://bit.ly/Alliance-A081801 | Alliance Member Site

Alliance A222001 (Hot Flashed in Men/Androgen Deprivation Therapy)

Bradley Stish, MD, of the Mayo Clinic, leads Alliance A222001 (A randomized, double-blind, placebo-controlled phase II study of oxybutynin versus placebo for the treatment of hot flashes in men receiving androgen deprivation therapy). This phase II trial compares the effect of oxybutynin versus placebo for reducing hot flashes in men receiving androgen deprivation (hormone) therapy for the treatment of prostate cancer. Androgen deprivation therapy decreases testosterone and other androgens through medications or surgical removal of the testicles. Relative to placebo, low- or high-dose oxybutynin may reduce hot flashes in men receiving androgen deprivation therapy. The trial opened on July 30, 2021. Learn more: https://bit.ly/Alliance-A222001 | Alliance Member Site

 

 

 

Read more articles in this month's e-newsletter: